title: Phase II study of teniposide in advanced breast cancer.
abstract: In a phase II study, 19 patients with previously treated, advanced breast cancer received 50 mg/m2 teniposide (VM-26) i.v. on days 1-5 every 3 weeks. One partial response (PR) (5%) was observed. Toxicity consisting of leukopenia and thrombocytopenia was frequent and severe. VM-26 has minimal therapeutic activity when given at this dose and on this schedule to patients with heavily pretreated metastatic breast cancer.
authors.affiliation: Department of Oncology, Herlev Hospital, University of Copenhagen, Denmark.
authors.forename: J
authors.initials: J
authors.lastname: Boas
authors.forename: D
authors.initials: D
authors.lastname: Rasmussen
authors.forename: O P
authors.initials: OP
authors.lastname: Hansen
authors.forename: S A
authors.initials: SA
authors.lastname: Engelholm
authors.forename: P
authors.initials: P
authors.lastname: Dombernowsky
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
chemical_list: D013713:Teniposide; D011034:Podophyllotoxin